Is CEL p.Gly134= (c.402C>G) pathogenic?

CEL p.Gly134= (c.402C>G) is classified Benign/Likely benign in CEL (ClinVar, Multiple submitters, 6 submitters; last evaluated 2025-03-13). Rare (popmax 0.809%, mid); Associated with maturity-onset diabetes of the young type 8.

What condition is associated with CEL p.Gly134= (c.402C>G)?

CEL p.Gly134= (c.402C>G) is associated with maturity-onset diabetes of the young type 8 (ClinVar).

How common is CEL p.Gly134= (c.402C>G) in the general population?

CEL p.Gly134= (c.402C>G) is rare (popmax 0.809%, mid) (gnomAD).

How is MODY inherited?

Typically Autosomal dominant, Not applicable (Orphanet). A genetic counselor can assess individual risk for a family.

CEL p.Gly134=

c.402C>G · rs150358550 · VCV713280

Benign/Likely benign Multiple submitters

Classification

Benign/Likely benign

ClinVar

Review

Multiple submitters ★★☆☆

ClinVar · 6 submitters

gnomAD v4.1

Rare

rare (popmax 0.809%, mid)

Conditions

maturity-onset diabetes of the young type 8

Computational evidence

Protein change
Missense predictors do not apply to this variant type; conservation carries the signal.
Splicing
SpliceAI	—	not assessed · no allele here is in the release
Constraint at this position
Conservation	phyloP -0.84	GERP 0.21, phastCons 0.005
Overall
CADD	3.757	PHRED · no single calibrated threshold — expert panels disagree

Population frequency

gnomAD v4.1 · exomes + genomes

Grpmax group 0.809% Middle Eastern · 49/6,060 alleles

Filtering AF 0.628% ClinGen BA1/BS1 input FAF95, joint · FAF99 0.564%

Overall 0.499% 8,061/1,613,938 alleles · rare exomes 7,388/1,461,616 · genomes 673/152,322 · joint denominator

Ancestry group	Frequency	1 in
Finnishnot grpmax-eligible	0.91%	110
Middle Easterngrpmax	0.809%	124
Amishnot grpmax-eligible	0.658%	152
European (non-Finnish)	0.539%	186
Admixed American	0.528%	189
Ashkenazi Jewishnot grpmax-eligible	0.426%	235
South Asian	0.384%	260
Remaining individualsnot grpmax-eligible	0.354%	283
African / African-American	0.0706%	1,416
East Asian	0.00223%	44,880

Finnish shows a higher raw frequency than the grpmax group above it. gnomAD excludes bottlenecked groups — Finnish, Ashkenazi Jewish, Amish and “Remaining individuals” — from grpmax, because founder effects make their frequencies unrepresentative for filtering. The table is sorted by frequency, so an excluded group can sit above the grpmax row.

Rarity supports pathogenicity (ACMG PM2); frequency above a disease-specific BA1/BS1 threshold argues against it. A variant frequent in one ancestry group can be near-absent in others, so a single global figure can mislead.

Variant & gene context

Gene: CEL
Protein: p.Gly134=
Coding: c.402C>G
MANE Select: NM_001807
dbSNP: rs150358550
Type: single nucleotide variant
Location: chr9:133065101 (GRCh38)
Gene constraint: LOEUF 0.972 · pLI <0.01 (gnomAD)
Structure: AlphaFold pLDDT 84.10 · 7 PDB

Full CEL gene report on Sugi Atlas → Gene function, pathways, protein structure, interactions & more

Disease context

maturity-onset diabetes of the young type 8 — disease report on Sugi Atlas → Associated genes, phenotypes, clinical trials & treatments

For MODY (Orphanet):

Inheritance: Autosomal dominant, Not applicable
Onset: Adolescent, Adult, Childhood
Prevalence: 1-5 / 10 000 (Europe)

Similar variants

CEL p.Gly134Ser Conflicting classifications of pathogenicity ★ same residue
CEL c.67-3C>A Uncertain significance ★★ same condition
CEL p.Ala295Ser Uncertain significance ★★ same condition
CEL p.Ala548Glu Uncertain significance ★★ same condition
CEL p.Ala722Val Uncertain significance ★★ same condition
CEL p.Arg116Gln Uncertain significance ★★ same condition
CEL p.Arg185Trp Uncertain significance ★★ same condition
CEL p.Arg443Trp Uncertain significance ★★ same condition

Built on 18 open, versioned datasets — ClinVar, gnomAD, AlphaMissense, REVEL, ClinGen & more — plus Sugi Variant's own cross-source analysis. Source data 2026-01–2026-10, ClinVar 2026-10. Full sources & versions →

Cite Sugi Variant

Gür T. Sugi Variant: A Deterministic Per-Variant Germline Reference from a Knowledge Graph for Humans and AI Agents. 2026. doi:10.5281/zenodo.21509445. This variant: https://sugi.bio/variant/cel-p-gly134 (accessed [today's date]).

Preprint & method: sugi.bio/variant/method Machine-readable: this page as Markdown